Cambridge-based Merrimack halts cancer drug trial, spurring further stock slide
A bad year at Cambridge-based Merrimack Pharmaceuticals got worse on Wednesday when the company announced that it was halting a midstage trial of a breast cancer drug, sending its shares tumbling.
Merrimack (Nasdaq: MACK) said it had decided to stop the Phase 2 study of MM-302, a treatment for metastatic breast cancer patients who have previously received three treatments developed by Genentech: Herceptin, Perjeta and Kadcyla.
Progression-free survival — a key measure of how long a patie nt can…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Max Stendahl Source Type: news
More News: American Health | Breast Cancer | Cancer | Cancer & Oncology | Health Management | Herceptin | Study